The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia

Leukemia and Lymphoma

Volumn 51, Issue 6, 2010, Pages 1115-1120

  Zhong, Yuejiao ^a   Chen, Baoan ^a   Feng, Jifeng ^b   Cheng, Lu ^c   Li, Yufeng ^d   Qian, Jun ^e   Ding, Jiahua ^a   Gao, Feng ^a   Xia, Guohua ^a   Chen, Ningna ^a   Lu, Zuhong ^c  

^a SOUTHEAST UNIVERSITY   (China)

^b Jiangsu Province Cancer Institute   (China)

^c Southeast University   (China)

^d THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^e Zhenjiang No 1 People's Hospital   (China)

Author keywords

AML; JAK2; SNPs

Indexed keywords

CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; JANUS KINASE 2; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CLINICAL TRIAL; ETHNOLOGY; GENETICS; LEUKEMIA, MYELOID, ACUTE; MASS SPECTROMETRY; MIDDLE AGED; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTARABINE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REMISSION INDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953500552     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003774960     Document Type: Article

References (17)

1. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006;6:671-679.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148. (Pubitemid 40663494)
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
4. Kratz CP, Boll S, Kontny U, Schrappe M, Niemeyer CM, Stanulla M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006;20:381-383.
5. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434-1436.
6. Zhang SJ, Li JY, Li WD, Song JH, Xu W, Qiu HX. The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Clin Lab Haematol 2007;29:71-72.
7. Schnittger S, Bacher U, Kern W, Schroder M, Haferlach T, Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006;20:2195-2197.
8. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008;111: 2785-2789.
9. Barragan E, Collado M, Cervera J, et al. The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 2007;3:947-953.
10. Bü chner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standarddose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-4124.
11. Bolaños-Meade J, Guo C, Gojo I, Karp JE. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leuk Rese 2004;28:571-577.
12. Fagerlund TH, Braaten O. No pain relief from codeine? An introduction to pharmacogenomics. Acta Anaesthesiol Scand 2001;45:140-149.
13. Rothenberg ML, Meropol NJ, Poplin EA, van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807.
14. Pardanani A, Lasho TL, Finke CM, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010;24: 110-114.
15. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446-449.
16. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008;49:388-397.
17. Sarolta N, Hajnalka A, ZoltanM, Nora L, Sandor L, TamasM. Clinical characteristics of JAK2 V617F mutation positive acute myeloid leukemia. Blood 2006;108(Suppl. 1): (Abstract 4508).